Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Cycle of Intravenous Immunoglobulin as Adjuvant to Rituximab in Patients With Pemphigus: A Retrospective Cohort Study at a Tertiary Referral Center

NCT06949241 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06949241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06949241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Cycle of Intravenous Immunoglobulin as Adjuvant to Rituximab in Patients With Pemphigus: A Retrospective Cohort Study at a Tertiary Referral Center
Lead sponsor
Ruijin Hospital
Phase
Observational
Overall status
Active, not recruiting
Start date
December 1, 2019
Completion date
February 2, 2026
Enrollment
76 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

intravenous immunoglobulin, pemphigus disease, rituximab (rtx)